Novartis, Roche, Genentech fined €444.85 million in France in AMD treatment case
The French competition authority, Autorité de la concurrence, has fined the pharmaceutical groups Novartis, Roche and Genentech, a combined €444.85 million for abuse of dominant position to impose the use of the drug Lucentis over its cheaper alternative Avastin in the treatment of age-related macular degeneration (AMD).
To continue reading this article register now.
Already an Eyewear Intelligence subscriber? Sign in here.
Become a member today for full access from just €7,29 a week!
Buying a membership today will give you:
- Unlimited access to ewintelligence.com - all insight and analysis available online
- Our executive edition of Eyewear Intelligence (Digital Edition) - the must-read for all decision-makers in the industry
- Weekly E-mail Briefing from the Chief Editor with the lastest analysis and most important industry developments
- Case studies and best practices on business challenges
- Guest chronicles, interviews, insights from industry experts and leaders that are shaping the future of the industry
- Access to over 11,500 articles and analyses in the archive
- Personal library to save articles and track your key content
- Powerful search and intuitive navigation
Or sign-up for a trial month for just 9,90€. To continue reading this article register now.